-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: keymaster@town.hall.org Originator-Key-Asymmetric: MFkwCgYEVQgBAQICAgADSwAwSAJBALeWW4xDV4i7+b6+UyPn5RtObb1cJ7VkACDq pKb9/DClgTKIm08lCfoilvi9Wl4SODbR1+1waHhiGmeZO8OdgLUCAwEAAQ== MIC-Info: RSA-MD5,RSA, J6Y1EGbfMgR3JmYiz42bVnsWa3bS4H9WJ0KX1IZlEqKJRjX0f0elCXgzi8haHOKB E108sdAUKKGIw9+A7MwurA== 0000950123-95-001987.txt : 199507180000950123-95-001987.hdr.sgml : 19950718 ACCESSION NUMBER: 0000950123-95-001987 CONFORMED SUBMISSION TYPE: 8-K/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 19950717 ITEM INFORMATION: Financial statements and exhibits FILED AS OF DATE: 19950717 SROS: AMEX FILER: COMPANY DATA: COMPANY CONFORMED NAME: CAMBREX CORP CENTRAL INDEX KEY: 0000820081 STANDARD INDUSTRIAL CLASSIFICATION: CHEMICALS & ALLIED PRODUCTS [2800] IRS NUMBER: 222476135 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-10638 FILM NUMBER: 95554342 BUSINESS ADDRESS: STREET 1: ONE MEADOWLANDS PLZ CITY: E RUTHERFORD STATE: NJ ZIP: 07073 BUSINESS PHONE: 2018043000 MAIL ADDRESS: STREET 1: ONE MEADOWLANDS PLAZA CITY: E. RUTHERFORD STATE: NJ ZIP: 07073 8-K/A 1 AMENDMENT NO. 2 TO FORM 8-K 1 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A AMENDMENT NO. 2 TO CURRENT REPORT ON FORM 8-K Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 JULY 17, 1995 (Date of earliest event reported) CAMBREX CORPORATION (Exact name of registrant as specified in its charter) DELAWARE (State or other jurisdiction of incorporation) 1-10633 22-2476135 (Commission File Number) (IRS Employer Identification No.) ONE MEADOWLANDS PLAZA EAST RUTHERFORD, NEW JERSEY 07073 (Address of principal executive offices) (Zip Code) (201) 804-3000 (Registrant's telephone number, including area code) Page 1 of 7 2 AMENDMENT NO. 2 The undersigned registrant hereby amends the following portion of its Current Report on Form 8-K filed October 27, 1994, as amended on a Form 8-K/A filed on December 29, 1994 containing Amendment No. 1 to Current Report on Form 8-K, as set forth in the pages attached hereto: Item 7. Financial Statements and Exhibits Filed as part of this Amendment No. 2 are the historical interim condensed combined unaudited financial statements of the Nobel/Profarmaco Group for the period January 1, 1994 through September 30, 1994. Page 2 of 7 3 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Amendment No. 2 to be signed on its behalf by the undersigned hereunto duly authorized. CAMBREX CORPORATION (Registrant) Dated: July 17, 1995 By:/s/ PETER E. THAUER ----------------------------- Peter E. Thauer Vice President-Law and Environment, General Counsel and Secretary Page 3 of 7 4 NOBEL/PROFARMACO GROUP CONDENSED COMBINED BALANCE SHEET (UNAUDITED) (IN THOUSANDS)
SEPTEMBER 30, 1994 ------------- ASSETS Current assets: Cash and cash equivalents............................... $ 5,464 Trade and other receivables............................. 23,032 Inventories............................................. 24,342 Other current assets.................................... 1,493 -------- Total current assets............................ 54,331 Property, plant and equipment, net........................ 55,262 Intangible assets, net.................................... 413 -------- Total assets.................................... $110,006 ======== LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Accounts payable and accrued liabilities................ $ 20,120 Income taxes payable.................................... 3,018 Short term borrowings and current portion of long term debt............................................. 2,062 -------- Total current liabilities....................... 25,200 Long-term debt............................................ 1,330 Other noncurrent liabilities.............................. 7,849 -------- Total liabilities............................... 34,379 Net investment in Nobel/Profarmaco Group.................. 75,627 -------- Total liabilities and net investment in Group... $110,006 ========
See accompanying notes to unaudited condensed combined financial statements. Page 4 of 7 5 NOBEL/PROFARMACO GROUP CONDENSED COMBINED INCOME STATEMENT (UNAUDITED) (IN THOUSANDS)
NINE MONTHS ENDED SEPTEMBER 30, 1994 ------------------ Net revenues ........................................ $82,532 Operating expenses: Cost of goods sold ................................ 54,205 Selling, general and administrative expenses ...... 13,422 Research and development .......................... 2,304 ------- Total operating expenses ........................ 69,931 ------- Operating profit .................................... 12,601 Other (income) expenses: Interest expense - net ............................ 409 Other - net ....................................... (233) ------- Income before income taxes .......................... 12,425 Provision for income taxes .......................... 4,160 ------- Net income .......................................... $ 8,265 =======
See accompanying notes to unaudited condensed combined financial statements. Page 5 of 7 6 NOBEL/PROFARMACO GROUP CONDENSED COMBINED STATEMENT OF CASH FLOWS (UNAUDITED) (IN THOUSANDS)
NINE MONTHS ENDED SEPTEMBER 30, 1994 ------------------ Cash flows from operations: Net income .............................................. $ 8,265 Depreciation and amortization ........................... 4,271 Changes in assets and liabilities: Receivables ........................................... (1,442) Inventories ........................................... 5,088 Other current assets .................................. (770) Accounts payable and accrued liabilities .............. 2,661 Income taxes payable .................................. 3,498 Other noncurrent assets and liabilities ............... 707 -------- Net cash provided from operations...................... 22,279 -------- Cash flows from investing activities: Capital expenditures .................................... (13,608) Other ................................................... (838) -------- Net cash (used in) investing activities ............... (14,445) -------- Cash flows from financing activities: Net activity with parent Company ........................ (1,131) Long-term debt activity (including current portion): Repayments ............................................ (9,237) -------- Net cash (used in) financing activities ............... (10,368) Effect of exchange rate changes on cash ................. 725 -------- Net decrease in cash .................................... (1,809) Cash at beginning of period ............................. 7,273 -------- Cash at end of period ................................. $ 5,464 --------
See accompanying notes to unaudited condensed combined financial statements. Page 6 of 7 7 NOBEL/PROFARMACO GROUP NOTES TO CONDENSED COMBINED FINANCIAL STATEMENTS (UNAUDITED) (IN THOUSANDS) (1) Basis of Presentation The combined financial statements of the Nobel/Profarmaco Group (hereafter referred to as the "Group") includes the accounts of Nobel Chemicals AB, Nobel Chemicals International AB, Profarmaco Nobel S.r.l., and three sales companies. The accompanying unaudited Condensed Combined Financial Statements have been prepared from the records of the Group. In the opinion of management, the financial statements include all adjustments, consisting of only normal recurring accruals, necessary for a fair presentation of financial position and results of operations in conformity with generally accepted accounting principles. These interim financial statements should be read in conjunction with the combined audited financial statements of the Nobel/Profarmaco Group for the year ended December 31, 1993. (2) Inventories Inventories are stated at the lower of cost, determined on a first-in, first-out basis, or market and include material, labor and overhead. Inventories at September 30, 1994 consist of the following: Finished goods . . . . . . . . $15,335 Work in process . . . . . . . . 5,842 Raw materials . . . . . . . . . 2,434 Supplies . . . . . . . . . . . 731 ------- $24,342 =======
(3) Debt All debt was satisfied by Akzo Nobel AB, the Group's parent, prior to the purchase of the Group by Cambrex in October 1994. Page 7 of 7 -----END PRIVACY-ENHANCED MESSAGE-----